Use of antipsychotics and risk of cerebrovascular events in schizophrenic patients: A nested case-control study

Journal of Clinical Psychopharmacology

Volumn 33, Issue 3, 2013, Pages 299-305

  Hsieh, Pei Hua ^a   Hsiao, Fei Yuan ^a   Gau, Susan Shur Fen ^b   Gau, Churn Shiouh ^a,c,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c Center for Drug Evaluation   (Taiwan)

^d Executive Yuan   (Taiwan)

Author keywords

antipsychotics; cerebrovascular events; schizophrenia; stroke

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CONTRACEPTIVE AGENT; FLUPENTIXOL; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PROCHLORPERAZINE; RISPERIDONE; STEROID; VALPROIC ACID; WARFARIN;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; POPULATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; TAIWAN; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; DATABASES, FACTUAL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK; SCHIZOPHRENIA; STROKE; TAIWAN; TIME FACTORS;

EID: 84877584020     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182900dfe     Document Type: Article

References (37)

1. World Health Organization. WHO Y The top 10 causes of death. Available at: http: //www.who.int/mediacentre/factsheets/fs310/en/index.html. Accessed November 15, 2011.
2. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005; 10: 79-104.
3. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006; 14: 191-210.
4. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002; 167: 1269-1270.
5. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ. 2004; 170: 1395.
6. Kleijer BC, van Marum RJ, Egberts AC, et al. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol. 2009; 23: 909-914.
7. Haupt M, Cruz-Jentoft A, Jeste D. Mortality in elderly dementia patients treated with risperidone. J Clin Psychopharmacol. 2006; 26: 566-570.
8. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007; 146: 775-786.
9. Layton D, Harris S, Wilton LV, et al. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol. 2005; 19: 473-482.
10. Kales HC, Valenstein M, Kim HM, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007; 164: 1568-1576; quiz 623.
11. Barnett MJ,Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol. 2007; 27: 595-601.
12. Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry. 2005; 66: 1090-1096.
13. Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005; 17: 617-629.
14. Percudani M, Barbui C, Fortino I, et al. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol. 2005; 25: 468-470.
15. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008; 337: a1227.
16. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002; 94: 1-26.
17. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996; 312: 1215-1218.
18. D'Agostino RB Jr, D'Agostino RB Sr. Estimating treatment effects using observational data. JAMA. 2007; 297: 314-316.
19. Sacchetti E, Turrina C, Valsecchi P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Saf. 2010; 33: 273-288.
20. Hsiao FY, Yang CL, Huang YT, et al. Using Taiwan's National Health Insurance Research Databases for Pharmacoepidemiology Research. J Food Drug Anal. 2007; 15: 99-108.
21. Gau SS, Chung CH, Gau CS. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. J Clin Psychopharmacol. 2008; 28: 271-278.
22. Gau CS, Chang CJ, Tsai FJ, et al. Association between mood stabilizers and hypothyroidism in patients with bipolar disorders: a nested, matched case-control study. Bipolar Disord. 2010; 12: 253-263.
23. Wu CS, Wang SC, Cheng YC, et al. Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry. 2011; 168: 511-521.
24. Gau SS, Chao PF, Lin YJ, et al. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study. J Clin Psychopharmacol. 2008; 28: 509-517.
25. Chien IC, Hsu JH, Bih SH, et al. Prevalence, correlates, and disease patterns of antipsychotic use in Taiwan. Psychiatry Clin Neurosci. 2008; 62: 677-684.
26. Curkendall SM, Mo J, Glasser DB, et al. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry. 2004; 65: 715-720.
27. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005; 353: 2335-2341.
28. Sacchetti E, Trifiro G, Caputi A, et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol. 2008; 22: 39-46.
29. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet. 2000; 356: 1219-1223.
30. Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010; 341: c4245.
31. Laredo L, Vargas E, Blasco AJ, et al. Risk of cerebrovascular accident associated with use of antipsychotics: population-based case-control study. J Am Geriatr Soc. 2011; 59: 1182-1187.
32. Allenet B, Schmidlin S, Genty C, Bosson JL. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf. 2012; 21: 42-48.
33. Boullin DJ, Grimes RPJ. Increased platelet aggregation on patients receiving chlorpromazine: responses to 5-hydroxytryptamine, dopamine and N-dimethyl dopamine. Br J Clin Pharmac. 1976; 3: 649-653.
34. Orr MW, Knox JM, Allen R, et al. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients. Br J Clin Pharmac. 1981; 11: 255-259.
35. Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 1996; 124: 57-73.
36. De Clerck F, Somers Y, Mannaert E, et al. In vitro effects of risperidone and 9-hydoxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis. Clin Ther. 2004; 26: 1261-1273.
37. Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008; 105: 175-187.